Springe direkt zu Inhalt

634. Anti-inflammatory IL-8 Regulation via an Advanced Drug Delivery System at the Oral Mucosa

M. Witt, M. Cherri, M. Ferraro, C. Yapto, K. Vogel, L. Schmidt, R. Haag, K. Danker, H. Dommisch – 2023

Oral inflammatory diseases are highly prevalent in the worldwide population. Topical treatment of inflammation is challenging due to dilution effects of saliva and crevicular fluid. Thus, there is a great medical need to develop smart anti-inflammatory drug delivery systems for mucosa treatment. We compared two promising anti-inflammatory dendritic poly(glycerol-caprolactone) sulfate (dPGS-PCL) polymers for their applicability to the oral mucosa. Using an ex vivo porcine tissue model, cell monolayers, and full-thickness 3D oral mucosal organoids, the polymers were evaluated for muco-adhesion, penetration, and anti-inflammatory properties. The biodegradable dPGS-PCL97 polymers adhered to and penetrated the masticatory mucosa within seconds. No effects on metabolic activity and cell proliferation were found. dPGS-PCL97 revealed a significant downregulation of pro-inflammatory cytokines with a clear preference for IL-8 in cell monolayers and mucosal organoids. Thus, dPGS-PCL97 exhibits excellent properties for topical anti-inflammatory therapy, suggesting new therapeutic avenues in the treatment of oral inflammatory diseases.

Title
634. Anti-inflammatory IL-8 Regulation via an Advanced Drug Delivery System at the Oral Mucosa
Author
M. Witt, M. Cherri, M. Ferraro, C. Yapto, K. Vogel, L. Schmidt, R. Haag, K. Danker, H. Dommisch
Date
2023
Identifier
DOI: 10.1021/acsabm.3c00024
Source(s)
Citation
ACS Appl. Bio Mater., 2023, 6, 6, 2145–2157
Type
Text